Lataa...
Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells
Protein tyrosine kinase 6 (PTK6, also called BRK) is overexpressed and activated in human prostate cancer. Loss of the tumor suppressor PTEN, a frequent event in prostate cancer, leads to PTK6 activation at the plasma membrane and its oncogenic signaling. The small molecule inhibitor vemurafenib, al...
Tallennettuna:
| Julkaisussa: | Mol Cancer Ther |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693941/ https://ncbi.nlm.nih.gov/pubmed/30926642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0862 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|